Earnings Report

Burjeel Holdings

Q1 26

1. Company Overview & Earnings Context

Burjeel Holdings reported its Q1 2026 results, delivering a solid performance with steady revenue growth and strong profit expansion, supported by rising patient volumes and operating leverage.

2. Financial Performance Snapshot

  • Revenue: AED 1.34B (+5.1% YoY)

  • EBITDA: AED 201M (+11.2% YoY), margin 15.0%

  • Net profit: AED 57M (+44.5% YoY)

  • Net profit margin: 4.2% (vs 3.1%)

  • Operating cash flow: AED 161M (+13.1% YoY)

  • Free cash flow conversion: 65%

3. Operational Highlights & Key Metrics

  • Patient visits: 1.8M (+7.2% YoY)

  • Outpatient growth: +7.3% YoY, utilization 70%

  • Inpatient growth: +5.9% YoY

  • Bed occupancy: 67%

  • Surgeries performed: 20,860

  • Segment highlights:

    • Hospitals: AED 1.19B revenue (+5.5%), ~89% of total

    • Medical Centers: AED 118M revenue (+9.3%)

    • Hospitals EBITDA: AED 242M (+12.2%)

4. Key Performance Drivers

Burjeel’s Q1 2026 performance was driven by volume growth and improving efficiency, as outlined in the MD&A (pages 5–7):

  • Patient volume growth (+7.2%) supported by network expansion and strong demand for specialized care

  • Revenue growth (+5.1%), impacted slightly by pricing changes under the Unified Procurement Program (UPP)

  • EBITDA margin expansion, driven by procurement optimization and cost discipline

  • Strong operating leverage, translating into 44% growth in net profit

  • Ramp-up of new facilities, with short-term drag but long-term earnings upside

Overall, growth was volume-led with improving profitability as assets scale.

5. Outlook & Forward Guidance

From management guidance (page 14):

  • Revenue expected to grow at low double-digit CAGR

  • EBITDA margins targeted to expand to low-20% range

  • Continued network expansion across UAE and KSA

  • Focus on high-acuity specialties and complex care

  • Capex pipeline (~AED 1B) to support growth and digital transformation

  • Leverage to remain controlled, with net debt/EBITDA <2.5x

6. ???? Investor Takeaway

Burjeel delivered a solid Q1 2026 with strong profit growth driven by rising patient volumes and margin expansion, positioning the business for scalable earnings growth as new assets mature.


Get in Touch

Speak to
UAE Stock Talks Team

Whether you need help navigating the platform, have a data query, or want to explore partnership opportunities — our team is here for you.

Support & Help
Feature Requests
Business Partnerships
Data Corrections